Vaccines are among the most effective tools in medicine, but no vaccine works perfectly in every person every time. Vaccine failure happens when someone who has been vaccinated still gets infected or loses protection over time, and the reasons span everything from your individual biology to a virus mutating faster than manufacturers can keep up. Understanding why it happens puts the occasional news story about breakthrough infections into proper perspective and helps you make smarter decisions about boosters and timing.
Two Distinct Types of Failure
Researchers draw a line between two fundamentally different problems. Primary vaccine failure means your immune system never mounted a meaningful response to the vaccine in the first place. You got the shot, but your body did not produce adequate antibodies or immune memory. Secondary vaccine failure is the opposite story: the vaccine worked initially, but your protection faded over months or years until it was no longer enough to keep you from getting sick.1PubMed Central. Primary vaccine failure to routine vaccines: Why and what to do? These two categories have different causes, different timelines, and often different solutions. A person who never responded may need a different vaccine formulation or an extra dose, while a person whose immunity waned simply needs a booster at the right time.
How Age Reshapes the Immune Response
One of the most consistent predictors of vaccine failure is age, and it cuts in both directions. In older adults, the immune system gradually loses its edge through a process researchers call immunosenescence. The structures in your lymph nodes where immune cells learn to recognize threats become less efficient, and the cells themselves become less responsive. On top of that, older adults tend to have a baseline level of chronic, low-grade inflammation that further interferes with mounting a clean immune response to a vaccine.2PubMed Central. How aging impacts vaccine efficacy: known molecular and cellular mechanisms and future directions This combination of sluggish immune cells and background inflammation makes older adults both more vulnerable to severe infections and less likely to get full protection from a standard vaccine dose.3PubMed. Vaccination in the elderly: The challenge of immune changes with aging
This is why high-dose flu vaccines exist for people over 65 and why COVID-19 booster schedules were more aggressive for older age groups. The vaccine itself is not flawed; it just needs to deliver a stronger signal to an immune system that is harder to wake up.
At the other end of the age spectrum, very young infants face a different obstacle. Antibodies passed from mother to baby during pregnancy and through breastfeeding provide crucial early protection, but those same maternal antibodies can interfere with vaccination. When a baby receives a vaccine, the mother’s circulating antibodies can neutralize the vaccine’s components before the infant’s own immune system gets a chance to respond. This is well documented with the measles vaccine, where maternal antibodies can block the infant from building its own antibody response.4PubMed Central. Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies The same interference has been confirmed experimentally with rotavirus vaccines, where the presence of maternal antibodies prevented pups from developing their own immune response after vaccination.5PubMed Central. Mechanisms of maternal antibody interference with rotavirus vaccination This is precisely why some childhood vaccines are scheduled for specific ages when maternal antibody levels have declined enough to let the infant’s own system take over.
When Your Genes Work Against You
Some people are genetically predisposed to respond poorly to certain vaccines, and the hepatitis B vaccine is the best-studied example. Roughly five to ten percent of the general population fails to produce protective antibodies after a complete hepatitis B vaccination series. That rate climbs dramatically in families: if a close relative is a known non-responder, the chance of non-response reaches around 58 percent, suggesting a strong genetic component.6PubMed Central. Overview of Hepatitis B Vaccine Non-Response and Associated B Cell Amnesia: A Scoping Review The genes most implicated are part of the immune system’s antigen-presentation machinery, which controls how effectively your cells display vaccine components to the immune cells that need to learn from them. In some people, certain genetic variants are associated with poor presentation, and the trait behaves recessively, meaning you need two copies of the relevant gene variant for it to substantially blunt your response.
This genetic dimension means that vaccine failure is not always a matter of lifestyle or health choices. For a small percentage of the population, the blueprint their immune system works from simply does not interact well with certain vaccine designs.
Obesity, Diabetes, and Chronic Inflammation
Your metabolic health has a measurable effect on how well vaccines work. Research on COVID-19 vaccines found that severe obesity accelerated the decline of neutralizing antibodies, contributing to higher rates of hospitalization from breakthrough infections compared to people at a healthy weight.7PubMed Central. Obesity negatively impacts maintenance of antibody response to COVID-19 vaccines Experimental work in animal models paints a consistent picture: both obese and diabetic animals showed weaker immune responses after vaccination than their healthy counterparts, with diabetic animals showing particularly blunted antibody and cellular immune responses. The underlying mechanism appears to be the chronic inflammation that accompanies both conditions, which creates a noisy immunological background that makes it harder for the vaccine signal to stand out.8PubMed Central. Impact of Metabolic States on SARS-CoV-2 Vaccine Responses in Mouse Models of Obesity and Diabetes
If you are living with obesity or poorly controlled blood sugar, this does not mean vaccines are useless. It means you may benefit from booster doses or from extra attention to timing, and it underscores why managing these conditions has ripple effects across your health in ways you might not have expected.
Immunosuppression and the Medication Factor
People whose immune systems are suppressed by disease or medication face some of the steepest challenges with vaccination. A review of dozens of systematic reviews spanning both COVID-19 and non-COVID vaccines found a wide range of responses depending on the specific condition. People with chronic kidney disease, HIV with normal immune cell counts, or inflammatory conditions tended to mount a reasonable response, often above 60 percent of what healthy controls achieved. Those on certain cancer treatments or with low immune cell counts from HIV fell into an intermediate range. And people who had received organ transplants, stem-cell transplants, or were taking B-cell-depleting medications like anti-CD20 therapy had the poorest responses, often below 40 percent of what a healthy person would achieve.9PubMed Central. Vaccination for the Prevention of Infection among Immunocompromised Patients: A Concise Review of Recent Systematic Reviews
Anti-B-cell therapies deserve special mention because their negative effect on vaccine responses is particularly severe and long-lasting compared to other immunosuppressive drugs.10PubMed Central. Efficacy of inactivated vaccines in patients treated with immunosuppressive drug therapy If you are on one of these medications, your doctor may recommend checking your antibody levels after vaccination or timing your shots to coincide with a period when the drug’s effect on your immune cells is at its lowest point. Some newer vaccine platforms show promise for immunocompromised patients, though the evidence base is still growing.11PubMed. Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review
Viruses That Outrun the Vaccine
Sometimes the vaccine has not failed at all; the target has moved. Influenza is the textbook example. The virus mutates constantly through a process called antigenic drift, where small changes in surface proteins gradually make the circulating strain look different enough from the vaccine strain that your antibodies have trouble recognizing it. This is why flu vaccine composition is reviewed before every season and sometimes still gets it wrong.12PubMed Central. Models for predicting the evolution of influenza to inform vaccine strain selection
The mismatch problem is bigger than most people realize. Over a recent ten-year stretch, only about a third of flu seasons showed a strong match between the vaccine strains and what actually circulated. In matched seasons, vaccine effectiveness hovered around 29 percent; in mismatched seasons, it dropped to essentially zero.13PubMed. Real-world effectiveness of influenza vaccine over a decade during the 2011-2021 seasons-Implications of vaccine mismatch Making the problem worse, the manufacturing process itself can introduce changes. When flu vaccines are grown in eggs, the virus sometimes picks up mutations that help it grow in eggs but subtly alter the very proteins the vaccine is supposed to train your immune system to recognize. Evidence suggests egg-adaptive mutations contributed to vaccine mismatch in more flu seasons than antigenic drift alone did over the 2011 to 2020 period.14PubMed Central. Seasonal influenza vaccine performance and the potential benefits of mRNA vaccines
A related phenomenon occurs with bacteria. When the pneumococcal vaccine was introduced, it targeted the seven most common disease-causing strains. As those strains declined, previously uncommon strains expanded to fill the ecological niche, a process called serotype replacement. Carriage of non-vaccine strains increased substantially, and in some populations, disease caused by those new strains partially offset the gains from vaccination.15PubMed Central. Serotype replacement in disease after pneumococcal vaccination Newer pneumococcal vaccines cover more strains to address this, but the broader lesson stands: pathogens exist in communities of competing variants, and removing some creates space for others.
Immunity That Fades
Even when a vaccine generates a strong initial response, protection does not always last as long as you would hope. Pertussis, or whooping cough, is a sobering case study. Countries that switched from whole-cell pertussis vaccines to newer acellular versions in the 1990s started seeing outbreaks in teenagers and young adults within a decade. The acellular vaccines produce fewer side effects but also prime the immune system differently, leading to protection that can start waning within two to three years after a booster dose.16PubMed Central. What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines
A large study found that the odds of developing pertussis increased by about 27 percent for each year since the last vaccination, and people who had received the acellular vaccine as their very first dose in infancy had roughly double the odds of later infection compared to those initially primed with the older whole-cell version.17PubMed Central. Effectiveness of pertussis vaccination and duration of immunity Studies during recent epidemics confirmed that protection from acellular vaccines faded faster, while receiving at least one whole-cell dose early in life provided more durable immunity regardless of what came after.18PubMed. Waning vaccine immunity in teenagers primed with whole cell and acellular pertussis vaccine: recent epidemiology
This kind of waning is why booster schedules exist and why they change over time as new data comes in. It is not a scandal that vaccines wear off. Some generate lifelong immunity, like measles, while others need periodic refreshing. The important thing is matching your booster schedule to the actual durability profile of each vaccine.
The Cold Chain and Other Logistics
Before a vaccine even reaches your arm, it has to survive a journey that can span thousands of miles through a tightly controlled temperature window, typically between 2°C and 8°C. When this “cold chain” breaks down, vaccine potency can silently degrade. A study monitoring nearly 50 vaccine distribution routes in Ukraine over several months found that while national and regional storage facilities maintained near-perfect temperature compliance, the picture deteriorated at the local level. Primary healthcare sub-offices maintained the correct temperature range only about 89 percent of the time during storage, and compliance during transport to those facilities dropped below 61 percent. Some facilities never maintained the correct temperature at any point during the monitoring period.19PubMed Central. Assessing vaccine cold chain storage and transport in Ukraine: a cross-sectional study
This is not just a developing-world problem. Power outages, refrigerator malfunctions, and human error during handling can compromise vaccines anywhere. A vaccine that has been exposed to freezing or excessive heat may look perfectly normal but produce a weaker immune response. You would never know it had been damaged, and neither would the person administering it.
Timing and Immune Imprinting
The interval between vaccine doses matters more than many people assume. Research comparing short and long gaps between a priming dose and a booster found that extending the interval to about 18 weeks instead of four produced a stronger germinal center response, the immune system’s training ground for producing high-quality, long-lived antibody-producing cells.20PubMed Central. Short or Long Interval between Priming and Boosting: Does It Impact on the Vaccine Immunogenicity? Rushing your second dose because you are eager to be “fully vaccinated” may actually sell your immune response short.
There is also a subtler timing issue called immune imprinting, sometimes referred to as original antigenic sin. When your immune system encounters a pathogen or vaccine for the first time, it builds a memory template. When you later encounter a related but different version of that pathogen, your immune system tends to reactivate the memory of the first encounter rather than building a fresh response tailored to the new variant. For influenza, this means that repeated vaccination against updated strains can sometimes produce antibodies that are more focused on the original strain you were exposed to years ago than on the current one.21PubMed Central. Impact of antigenic evolution and original antigenic sin on SARS-CoV-2 immunity This phenomenon complicates vaccine strategy for rapidly evolving viruses and is an active area of research.
The Gap Between Injection and Mucosal Protection
Most vaccines are injected into a muscle, which is excellent at generating antibodies in your bloodstream but less effective at building immune defenses in the mucous membranes of your nose, throat, and gut, which are the actual entry points for many respiratory and gastrointestinal infections. This mismatch helps explain why vaccinated people can still get infected even when their vaccine is working well at preventing severe disease.
Research on SARS-CoV-2 found a striking pattern: people who had been infected before vaccination had higher levels of mucosal antibodies after a breakthrough infection than people whose first encounter with the virus came after vaccination. More vaccinations without prior natural infection were actually associated with lower odds of having detectable mucosal antibodies.22PubMed Central. Impact of systemic SARS-CoV-2 vaccination on mucosal IgA responses to subsequent breakthrough infection This does not mean natural infection is preferable to vaccination. It means that injectable vaccines have an inherent limitation when it comes to blocking infection at the body’s surfaces, and it is one reason researchers are working on nasal and oral vaccine formulations that could train the immune system right where pathogens first land.
Breakthrough Infections Are Usually Milder
When people hear “vaccine failure,” they often picture the vaccine doing nothing at all. The reality is more nuanced. Even when a vaccinated person gets infected, the prior vaccination typically reduces the severity of the illness. Clinical trials and real-world data on COVID-19 vaccines consistently showed that vaccination was highly effective at preventing hospitalization and death, even when it did not fully prevent infection.23PubMed Central. A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant Breakthrough infections were uncommon and generally less severe than infections in unvaccinated people.24PubMed Central. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data
This distinction between preventing infection and preventing severe disease is crucial. A vaccine that keeps you out of the hospital but does not stop you from getting a sore throat and a runny nose has not “failed” in any meaningful sense. The framing matters because it shapes public trust and policy decisions.
Why Herd Immunity Fills the Gaps
For people whose immune systems genuinely cannot respond to vaccines, whether due to genetic non-response, organ transplants, or intensive chemotherapy, the protection of the surrounding community becomes a lifeline. When enough people in a population are vaccinated and immune, the pathogen struggles to find susceptible hosts and transmission slows dramatically. This is what makes herd immunity a collective safety net rather than just an individual benefit.
When vaccination rates drop, that net develops holes. Declining measles vaccination rates, for instance, have eroded herd immunity to the point where patients with immune deficiencies face increasing risk because even the protective antibody products used to shield them are becoming less effective as population-level immunity wanes.25PubMed. Herd immunity and primary immune deficiencies The people who pay the highest price for falling vaccination rates are rarely the ones making the choice to skip their shots.
Measuring Protection Is Not Straightforward
Part of the confusion around vaccine failure comes from how we measure whether a vaccine works. The standard approach for many decades has been to measure antibody levels in the blood, but antibodies are only part of the immune response. The traditional test for flu vaccines, which looks at whether antibodies can block a virus from clumping red blood cells, does not always accurately predict whether someone is protected from getting sick. Newer vaccine designs that target different parts of the virus produce antibodies that do not even show up on this classic test, which means they can look like failures when they are not.26PubMed Central. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model
There is also a meaningful gap between how a vaccine performs in a controlled trial and how it performs in the real world. Modeling work has shown that the usual way of measuring vaccine performance can actually underestimate its total impact, especially at lower coverage levels, because the standard calculation does not capture indirect benefits like reduced transmission in the community.27PubMed Central. Distinguishing vaccine efficacy and effectiveness A vaccine might look like it is performing at 60 percent effectiveness for individuals, but its true value to the population is higher once you account for the fact that every vaccinated person also reduces the risk to those around them. The numbers we hear on the news often do not capture this fuller picture, which can make vaccines seem less impressive than they actually are.